Moderna’s CEO told Bloomberg the company is curbing investments in some vaccine trials in response to political and public backlash in the United States. The shift reflects pressure on mRNA vaccine developers to balance broad pipeline ambitions with heightened regulatory and public scrutiny. Industry observers say the move could slow some non-COVID vaccine programs and recalibrate resource allocation across mRNA platforms, while competitors and partners reassess trial timelines and external engagement strategies.